{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:27:17Z","timestamp":1788989237118,"version":"build-2803163510"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Lung cancer has the highest risk of brain metastasis (BM) among all solid carcinomas. The emergence of BM has a significant impact on the selection of oncologic treatment for patients. Immune checkpoint inhibitors (ICIs) are the most promising treatment option for patients without druggable mutations and have been shown to improve survival in patients with non-small cell lung cancer (NSCLC) BM in clinical trials with good safety. Moreover, ICI has shown certain effects in NSCLC BM, and the overall intracranial efficacy is comparable to extracranial efficacy. However, a proportion of patients showed discordant responses in primary and metastatic lesions, suggesting that multiple mechanisms may exist underlying ICI activity in BM. According to studies pertaining to tumor immune microenvironments, ICIs may be capable of provoking immunity <jats:italic toggle=\"yes\">in situ<\/jats:italic>. Meanwhile, systematic immune cells activated by ICIs can migrate into the central nervous system and exert antitumor effects. This review summarizes the present evidence for ICI treatment efficacy in NSCLC BM and proposes the possible mechanisms of ICI treatment for NSCLC BMs based on existing evidence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002163","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:13:07Z","timestamp":1682658787000},"page":"1523-1531","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases"],"prefix":"10.1097","volume":"136","author":[{"given":"Yuxi","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"},{"name":"Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences, Beijing 100730, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","article-title":"Management of brain metastases according to molecular subtypes","volume":"16","author":"Soffietti","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"102067","DOI":"10.1016\/j.ctrv.2020.102067","article-title":"Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic","volume":"89","author":"Vilarino","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ctrv.2018.05.015","article-title":"Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment","volume":"68","author":"El Rassy","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"e001300","DOI":"10.1136\/jitc-2020-001300","article-title":"Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer","volume":"8","author":"Zhou","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"1758835920977137","DOI":"10.1177\/1758835920977137","article-title":"First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis","volume":"12","author":"Landre","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2018.04.039","article-title":"Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer","volume":"13","author":"Fehrenbacher","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","article-title":"Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer","volume":"129","author":"Crin\u00f2","year":"2019","journal-title":"Lung Cancer"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/jitc-2020-001007","article-title":"Outcomes to first-line pembrolizumab in patients with PD-L1-high (\u226550%) non-small cell lung cancer and a poor performance status","volume":"8","author":"Alessi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodriguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cllc.2020.10.014","article-title":"Combined immunotherapy and stereotactic radiotherapy improves neurologic outcomes in patients with non-small-cell lung cancer brain metastases","volume":"22","author":"Enright","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/cancers13071562","article-title":"Correlation of clinical parameters with intracranial outcome in non-small cell lung cancer patients with brain metastases treated with Pd-1\/Pd-L1 inhibitors as monotherapy","volume":"13","author":"Rounis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1002\/cncr.33196","article-title":"Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases","volume":"126","author":"Qian","year":"2020","journal-title":"Cancer"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","article-title":"Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO","volume":"23","author":"Scoccianti","year":"2021","journal-title":"Neuro Oncol"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3171\/2018.10.JNS181371","article-title":"Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases","volume":"132","author":"Singh","year":"2019","journal-title":"J Neurosurg"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2021.04.006","article-title":"Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy","volume":"156","author":"Lau","year":"2021","journal-title":"Lung Cancer"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/noab046","article-title":"The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis","volume":"23","author":"Jessurun","year":"2021","journal-title":"Neuro Oncol"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"670313","DOI":"10.3389\/fonc.2021.670313","article-title":"Combination of immune checkpoint inhibitors and anti-angiogenic agents in brain metastases from non-small cell lung cancer","volume":"11","author":"Fang","year":"2021","journal-title":"Front Oncol"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/1759-7714.13557","article-title":"Poor efficacy of anti-programmed cell death-1\/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases","volume":"11","author":"Tozuka","year":"2020","journal-title":"Thorac Cancer"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2017.12.008","article-title":"Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases","volume":"116","author":"Gauvain","year":"2018","journal-title":"Lung Cancer"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"R30-20250602","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.3390\/cancers12123707","article-title":"Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a \u2018real-life\u2019 setting","volume":"12","author":"Skribek","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R31-20250602","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R32-20250602","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cllc.2020.10.017","article-title":"Outcomes in patients with non-small-cell lung cancer with brain metastases treated with pembrolizumab-based therapy","volume":"22","author":"Sun","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"R33-20250602","doi-asserted-by":"crossref","first-page":"12777","DOI":"10.2147\/OTT.S286600","article-title":"PD-1\/PD-L1 inhibitor combined with chemotherapy can improve the survival of non-small cell lung cancer patients with brain metastases","volume":"13","author":"Sun","year":"2020","journal-title":"Onco Targets Ther"},{"key":"R34-20250602","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00262-019-02462-1","article-title":"Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R35-20250602","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2016.05.031","article-title":"Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases","volume":"98","author":"Dudnik","year":"2016","journal-title":"Lung Cancer"},{"key":"R36-20250602","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s12094-021-02588-8","article-title":"Upfront pembrolizumab as an effective treatment start in patients with PD-L1 \u2265 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis","volume":"23","author":"Metro","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"R37-20250602","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"R38-20250602","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2119\/molmed.2015.00207","article-title":"Blood-brain barrier remodeling during brain metastasis Formation","volume":"22","author":"Wrobel","year":"2016","journal-title":"Mol Med"},{"key":"R39-20250602","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R40-20250602","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood-tumour barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R41-20250602","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3390\/cancers13040910","article-title":"Picturing breast cancer brain metastasis development to unravel molecular players and cellular crosstalk","volume":"13","author":"Figueira","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R42-20250602","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","article-title":"Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid","volume":"164","author":"Pluim","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"R43-20250602","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1158\/0008-5472.CAN-16-1711","article-title":"Quantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumors","volume":"77","author":"Mittapalli","year":"2017","journal-title":"Cancer Res"},{"key":"R44-20250602","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R45-20250602","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"R46-20250602","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1078-0432.CCR-15-0713","article-title":"Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma","volume":"22","author":"Pham","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R47-20250602","doi-asserted-by":"crossref","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","article-title":"Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking","volume":"115","author":"Taggart","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"R48-20250602","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"R49-20250602","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2021.03.017","article-title":"Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors","volume":"16","author":"Memmott","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R50-20250602","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R51-20250602","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijrobp.2020.04.018","article-title":"Programmed death receptor ligand one expression may independently predict survival in patients with non-small cell lung carcinoma brain metastases receiving immunotherapy","volume":"108","author":"Hulsbergen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R52-20250602","doi-asserted-by":"crossref","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R53-20250602","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1158\/1078-0432.CCR-19-2184","article-title":"Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival","volume":"26","author":"Pocha","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R54-20250602","doi-asserted-by":"crossref","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","article-title":"Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases","volume":"5","author":"Berghoff","year":"2016","journal-title":"Oncoimmunology"},{"key":"R55-20250602","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbrc.2018.03.053","article-title":"Programmed death ligand 1 expression and CD8(+) tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer","volume":"498","author":"Zhou","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R56-20250602","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41419-021-03410-7","article-title":"Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis","volume":"12","author":"Song","year":"2021","journal-title":"Cell Death Dis"},{"key":"R57-20250602","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12885-018-5214-8","article-title":"Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"key":"R58-20250602","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00262-020-02840-0","article-title":"Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape","volume":"70","author":"Song","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R59-20250602","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"R60-20250602","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cllc.2019.05.008","article-title":"PD-L1 expression of lung cancer cells, unlike infiltrating immune cells, is stable and unaffected by therapy during brain metastasis","volume":"20","author":"T\u00e9gl\u00e1si","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"R61-20250602","doi-asserted-by":"crossref","first-page":"e002230","DOI":"10.1136\/jitc-2020-002230","article-title":"Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer","volume":"9","author":"Moutafi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R62-20250602","doi-asserted-by":"crossref","first-page":"e002684","DOI":"10.1136\/jitc-2021-002684","article-title":"Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases","volume":"9","author":"Lu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R63-20250602","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-021-00151-w","article-title":"Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma","volume":"5","author":"Jiang","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"R64-20250602","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cam4.2905","article-title":"Characterization of the immune microenvironment in brain metastases from different solid tumors","volume":"9","author":"Jiang","year":"2020","journal-title":"Cancer Med"},{"key":"R65-20250602","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","article-title":"Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann Oncol"},{"key":"R66-20250602","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41598-018-20622-8","article-title":"Contraction of T cell richness in lung cancer brain metastases","volume":"8","author":"Mansfield","year":"2018","journal-title":"Sci Rep"},{"key":"R67-20250602","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann Oncol"},{"key":"R68-20250602","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/neuonc\/noab022","article-title":"Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling","volume":"23","author":"Schaffenrath","year":"2021","journal-title":"Neuro Oncol"},{"key":"R69-20250602","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"R70-20250602","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00262-020-02677-7","article-title":"Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer","volume":"70","author":"Failing","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R71-20250602","doi-asserted-by":"crossref","first-page":"e69578","DOI":"10.7554\/eLife.69578","article-title":"Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues","volume":"10","author":"Fan","year":"2021","journal-title":"Elife"},{"key":"R72-20250602","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/neuonc\/now309","article-title":"Evaluating the significance of density, localization, and PD-1\/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis","volume":"19","author":"T\u00e9gl\u00e1si","year":"2017","journal-title":"Neuro Oncol"},{"key":"R73-20250602","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"R74-20250602","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:04:26Z","timestamp":1748905466000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":74,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002163","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}